Person Responsible for Regulatory Compliance (PPRC) under MDR & IVDR
The EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) require all Manufacturers and Authorized Representatives to have a designated employee in their company who is responsible for regulatory compliance with the applicable MDR or IVDR requirements, the Person Responsible for Regulatory Compliance (PRRC).

WHAT ARE THE RESPONSIBILITIES OF THE PRRC?

The person responsible for regulatory compliance, permanently and continuously at disposal, shall at least be responsible for ensuring:

  1. the conformity of the devices is appropriately checked, in accordance with the quality management system (QMS) under which the devices are manufactured, before a device is released;
  2. the technical documentation and the EU declaration of conformity are drawn up and kept up-to-date;
  3. the post-market surveillance obligations are complied with in accordance with Article 10(10) of MDR and Article 10(9) of IVDR;
  4. the reporting obligations referred to in Articles 87-91 of MDR and Articles 82-86 of IVDR;
  5. in the case of investigational devices, the statement referred to in Section 4.1 of Chapter II of Annex XV of the MDR and Section 4.1 of Annex XIV of the IVDR.

The Manufacturer or Authorized Representative may appoint more than one PRRC. In this case, their respective areas of responsibility shall be put down in writing.

WHAT ARE THE QUALIFICATIONS OF THE PRRC?

Article 15(1) of both MDR and IVDR require the PRRC to have either:

  • A diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognized as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices or in vitro diagnostics.
  • 4 years of professional experience in regulatory affairs or in quality management systems in the medical device or in vitro diagnostic device fields.

The MDCG Guidance 2019-7 specifies that the professional experience in regulatory affairs or quality management should be related to the EU requirements in the field. Additionally, for manufacturers located outside the EU, it must be assumed that the PRRC should also be located outside the EU. On the other hand, for manufacturers located in the EU, it must be assumed that the PRRC should also be located in the EU.

It is important to note that the PRRC does not replace the manufacturer’s European Authorized Representative (EC REP) as these are two separate roles with different responsibilities and obligations under the MDR and IVDR.

The PRRC appointed should be an employee of the organization. Micro and small enterprises, e.g., with fewer than 50 full-time employees and less than €10 million in global sales are not required to have the PRRC within their organization and can outsource this role to a third party, while ensuring that such person is permanently and continuously at their disposal.

If you wish to know more information about the EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (UE) 2017/745, on medical devices
  2. Regulation (UE) 2017/746, on in vitro diagnostic medical devices
  3. MDCG 2019-7 – Guidance on Article 15 of the Medical Device Regulation (MDR) and in vitro Diagnostic Device Regulation (IVDR) regarding a ‘person responsible for regulatory compliance’ (PRRC)

further
reading

cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »
cosmetic products

Expected Restriction on the Use of Methyl Salicylate

The European Commission has notified the World Trade Organization (WTO) of a draft amendment to the Regulation (EC) No. 1223/2009 on cosmetic products. Annex III to Regulation will be amended, and the use of Methyl Salicylate in cosmetic products will be restricted.

Read More »